Titan Biotech (BOM:524717) Total Equity: ₹1,815 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524717 Titan Biotech Ltd BOM:524717
51 GF Score
Price ₹424.85
GF Value ₹145.03
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Titan Biotech Total Equity?

Titan Biotech BOM:524717 +1.47% 51 Total Equity is ₹1,815 Mil as of Mar. 2026. GuruFocus rates BOM:524717 with a GF Score™ of 51/100 and a GF Value™ of ₹145.03 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Titan Biotech's total equity for the quarter that ended in Mar. 2026 was ₹1,815 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Titan Biotech Total Equity Historical Data

* Premium members only.

The historical data trend for Titan Biotech's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Titan Biotech Total Equity Chart

Titan Biotech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 862.44 1,099.11 1,334.51 1,534.03 1,815.48

Titan Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,534.03 0.00 1,664.15 0.00 1,815.48
BOM:524717
51GF Score
Titan Biotech Ltd BOM:524717
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Titan Biotech Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Titan Biotech's Total Equity for the fiscal year that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=2138.848-323.373
=1,815

Titan Biotech's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=2138.848-323.373
=1,815

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of ₹1,815 Mil mean?
Titan Biotech (BOM:524717) has a Total Equity of ₹1,815 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Titan Biotech and its competitors.
Is Titan Biotech's Total Equity too high?
Titan Biotech's current Total Equity is ₹1,815 Mil. Overall, Titan Biotech has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Titan Biotech's Total Equity compare to VRTX and REGN?
Titan Biotech's Total Equity of ₹1,815 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Titan Biotech and its competitors. Titan Biotech's current Total Equity is ₹1,815 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Titan Biotech stock overvalued right now?
Based on GuruFocus' analysis, Titan Biotech (BOM:524717) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹145.03, compared to a current price of ₹424.85 — trading 192.9% above its estimated fair value. The current Total Equity is ₹1,815 Mil. Titan Biotech's overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Titan Biotech (BOM:524717), the current Total Equity is ₹1,815 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Titan Biotech (BOM:524717) Overvalued in 2026?

Based on GuruFocus' analysis, Titan Biotech stock appears to be overvalued. The current stock price of ₹424.85 is trading 192.9% above its estimated GF Value™ of ₹145.03. GuruFocus considers Titan Biotech to be Significantly Overvalued.

Key valuation signals for BOM:524717:

  • Total Equity: ₹1,815 Mil
  • GF Value™: ₹145.03 vs. price of ₹424.85 (192.9% above fair value)
  • GF Score™: 51/100 with 2 warning signs

No single metric tells the full story. See the BOM:524717 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Titan Biotech Business Description

Address Netaji Subhash Place, 903-909, 9th Floor, Bigjos Tower, New Delhi, IND, 110034
Titan Biotech Ltd is a manufacturer and exporter of biological products. It manufactures biological products such as peptone, malt extract, yeast extract, liver extract, bile extract, culture media, laboratory chemicals, plant growth promoters, and others. The biological products have applications in the field of pharmaceutical, nutraceutical, food and beverages, biotechnology and fermentation, cosmetic, veterinary and animal feed, agriculture industries, and others. The company's business activity falls within a single primary business segment, which is the business of Biological Products. The firm sells its products in India and also exports internationally, of which the majority of the revenue is derived from the sales made in India.
51GF Score

Get the complete analysis for BOM:524717

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹424.85
Price
₹145.03
GF Value